Last $92.91 USD
Change Today -5.55 / -5.64%
Volume 1.0M
BLUE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

bluebird bio inc (BLUE) Snapshot

Open
$97.27
Previous Close
$98.46
Day High
$97.67
Day Low
$91.02
52 Week High
01/14/15 - $106.23
52 Week Low
05/9/14 - $17.40
Market Cap
2.9B
Average Volume 10 Days
718.3K
EPS TTM
$-1.52
Shares Outstanding
31.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BLUEBIRD BIO INC (BLUE)

bluebird bio inc (BLUE) Related Businessweek News

No Related Businessweek News Found

bluebird bio inc (BLUE) Details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company’s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

124 Employees
Last Reported Date: 11/12/14
Founded in 1992

bluebird bio inc (BLUE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $392.5K
Chief Operating Officer
Total Annual Compensation: $321.7K
Chief Scientific Officer
Total Annual Compensation: $307.2K
Compensation as of Fiscal Year 2013.

bluebird bio inc (BLUE) Key Developments

bluebird bio, Inc. Announces Transition of Mitchell H. Finer from Chief Scientific Officer

bluebird bio, Inc. announced that Mitchell H. Finer, Ph.D., chief scientific officer, has decided to transition from his current role with bluebird bio over the next six months. At the end of this transition period, he will remain an important scientific voice at bluebird bio by serving on the company's scientific advisory board and continuing to share his experience and insights to benefit the company's scientific strategy. The company is now initiating the process of recruiting for a CSO replacement.

bluebird bio, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 02:30 PM

bluebird bio, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 02:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Nick Leschly, Chief Executive Officer, President and Director.

bluebird bio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM

bluebird bio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Jeffrey T. Walsh, Chief Operating Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $92.91 USD -5.55

BLUE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $4.14 USD +0.25
Sangamo BioSciences Inc $12.79 USD -0.41
View Industry Companies
 

Industry Analysis

BLUE

Industry Average

Valuation BLUE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 109.1x
Price/Book 10.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 114.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit www.bluebirdbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.